Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

UltiMalVax

Financiado

A Vaccine Targeting Eradication of Malaria

Malaria killed about 640 thousand people in 2020, largely young children in Africa. Rapid recent progress has led to two anti-sporozoite vaccine developers planning WHO prequalification applications in 2022. These include the new... ver más

30/04/2027

EUROPEAN VACCINE I...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

EUROPEAN VACCINE INITIATIVE E.V No se ha especificado una descripción o un objeto social para esta compañía.

Ver 10 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-21

HORIZON-HLTH-2022-DISEASE-06-03-two-stage: Vaccines 2.0 - developing the next... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

EUROPEAN VACCINE INITIATIVE...

481.25K€ | Lider

SPYBIOTECH LIMITED

N.D. | Participante

Serum Institute of India Pvt...

NEOVAC LTD

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2016-76080-R CARACTERIZACION DE LOS GLICOCONJUGADOS PRESENTES EN LAS SUPE... 97K€ Cerrado

PoEMM Plasmodium Exploitation of Liver-specific Methionine Metabol... 173K€ Cerrado

MARVAX Development of novel viral vectored vaccines against Marburg... 7M€ Cerrado

SAF2008-00743 ESTUDIO DE MARCADORES DE INMUNIDAD Y SUSCEPTIBILIDAD FRENTE... 121K€ Cerrado

BIO2016-77430-R EPITOPOS INMUNODOMINANTES DE MALARIA Y ENFERMEDADES CO-ENDEM... 169K€ Cerrado

SAF2016-81856-REDT RED TEMATICA DE ANTIVIRALES FRENTE A ENFERMEDADES ARBOVIRALE... 20K€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2023-04-21
Fecha Fin: 2027-04-30

Líder del proyecto

EUROPEAN VACCINE INITIATIVE E.V No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 3M€

Descripción del proyecto Malaria killed about 640 thousand people in 2020, largely young children in Africa. Rapid recent progress has led to two anti-sporozoite vaccine developers planning WHO prequalification applications in 2022. These include the new high efficacy R21/Matrix-M vaccine, to be supplied at the required large scale, and led by partners in this consortium. In parallel, recent progress with transmission-blocking malaria vaccines has led to substantial efficacy in a first direct skin feeding field trial. This opens up the prospect of a two-stage vaccine targeting both sporozoites and sexual-stage parasites that should have a major impact on malaria transmission, thereby enabling regional elimination and ultimate eradication. We propose here to develop such a vaccine assessing both established virus-like particle (VLP) vaccines in potent saponin adjuvants and also exciting new thermostable mRNA vaccines expressing the parasite antigens now showing high efficacy. Importantly, we will adopt new VLP design technologies, e.g. SpyCatcher bonding, that allow bivalent antigen display, to enable a single vaccine to protect against both the Plasmodium falciparum parasite, which causes most deaths, and the more widespread Plasmodium vivax parasite. A lead vaccine candidate will be down-selected based on well-studied pre-clinical efficacy models and induction of functional transmission-blocking antibodies, prior to GMP manufacture and a clinical trial in year 4. The consortium brings together academics, non-profits and a wide range of companies with both leading technologies and access to small and very large scale GMP manufacturing capacity. This programme builds on the recent success of several partners in the R21/Matrix-M programme and aims to accelerate the malaria eradication agenda by providing the first vaccine to tackle both major malaria parasite species, and confer both individual and community protection on the way to eradication.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores